Satralizumab is a monoclonal antibody that inhibits interleukin-6 and is an approved therapy for adults with neuromyelitis optica spectrum disorder. Satralizumab may slow bone loss and muscle atrophy to help prevent fractures and improve bone and muscle strength.
A Phase 2 study in Duchenne is actively recruiting.
This program is sponsored by Roche.
ACTIVELY RECRUITING | SHIELD DMD (A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy) (DMD) |
